gyn neoplasms (10%) Flashcards
what is the MC type of vaginal ca
squamous cell (95%) clear cell if DES exposure in utero
what is the MC type of vulvar ca
90% squamous
RFs for vulvar ca
HPV 16, 18, 31
DES
sx of vulvar ca
pruritis MC
asx, postcoital bleeding, vaginal DC
red/white ulcerative, crusted lesions
dx of vulvar ca
bx vulvar lesions
2 MC types of breast ca
ductal or lobular
RFs for breast ca
BRCA 1st deg relative 65yo+ inc # of menstrual cycles (nulliparity, 1st FT pregnancy >35yo, menarche <12yo, late menopause, never breastfed) inc estrogen (PCOS, obesity, hRT, OCPs)
what % of breast ca pts have NO RFs
75%
stages of breast ca
0- preCA, DCIS, LCIS
I-III- w.i breast/regional LN
IV- distant mets
types of breast ca
ductal- infiltrative MC, carcinoma in situ
lobular- infiltrative or carcinoma in situ
what is infiltrative ductal carcinoma associated w
lymphatic mets
esp axillary
where is the MC position for breast ca lump
upper outer quadrant
what type of nipple discharge may indicate breast ca
bloody
purulent
green
where are the MC mets from breast ca
liver
lung
bone
brain
what does page’s disease of the nipple look like
chronic eczematous itchy, scaling rash on nipples + areola
what does inflammatory breast cancer look like
red, swollen, warm itchy breast often w nipple retraction + peau d’orange
what causes peau d’orange and what is the prognosis
lymphatic obstruction
poor prognosis
what do you usu see on mammogram in breast ca
microcalcifications
spiculated masses
when is US used to screen for breast ca
women <40yo
how do you dx breast ca
biopsy- fine needle, large needle, core, open
tx options for breast ca
lumpectomy +/- XRT
mastectomy
remove axillary LN!!!
when do you do XRT for breast ca
s/p lumpectomy or mastectomy
when do you do chemo for breast ca
stage II-IV, inoperable disease
especially if ER negative
what are the neoadjuvant endocrine treatments for breast ca
antiestrogens (tamoxifen)
aromatase inhibitors (letrozole, anastrozole)
monoclonal ab tx (trastuzumab/herceptin)
tamoxifen uses and MOA
ER positive tumors
MOA- bind + block estrogen receptor in breast
aromatase inhibitors uses
letrozole, anastrozole
good in postmenopausal ER-positive tumors
monoclonal Ab use + ADRs
trastuzumab/herceptin HER2 positive (human epidermal growth factor receptors) ADR = cardiotoxic
mammogram screening guidelines
ACOG- q1yr starting at 40yo
clinical breast exam guidelines
q3yrs starting at 20yo –> q1yr after 40yo
breast self exam guidelines
monthly after 20yo
immediately after menstruation or on days 5-7
breast ca prevention in high risk pt
SERMs (tamoxifen or raloxifene) or aromatase inhibitors (letrozole, anastrozole)
high risk = postmenopausal or 35yo+ with high risk (BRCA)
usu done for 5yrs
which SERM is preferred for breast ca ppx, why and what are the cons of it
tamoxifen- more effective, more DVT + endometrial CA risk
what causes endometrial hyperplasia
unopposed estrogen (chronic anovulation, PCOS, perimenopause, obesity)
dx of endometrial hyperplasia
TVUS endo stripe >4
definitive = bx